StockNews.AI
RCKT
StockNews.AI
21 days

RCKT DEADLINE REMINDER: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Important Class Action Lawsuit Deadline

1. Rocket Pharmaceuticals faces class action for concealing trial safety concerns. 2. Allegations relate to RP-A501 trial and led to steep investor losses. 3. Company announced FDA clinical hold after a patient died in the trial. 4. Stock price fell nearly 37% over two trading days following the hold. 5. Investors from September 2024 to May 2025 may join the class action.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Legal complications and safety concerns typically drive stock prices down, as seen historically with other pharma companies facing lawsuits. For instance, companies like Valeant saw substantial price declines amidst similar allegations.

How important is it?

The legal action points to critical operational missteps, directly affecting investor confidence and valuation. As shares plummet and uncertainty creeps in, the potential for further investor withdrawals escalates.

Why Short Term?

Immediate investor reaction to legal news usually causes quick volatility, as seen with Biogen's stock manipulation allegations affecting prices significantly within weeks.

Related Companies

VRTXBMYPFE
, /PRNewswire/ -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses. Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, where it operates its research and clinical programs in genetic medicine. According to the complaint, the Company introduced a new immunomodulatory agent into the RP-A501 protocol, information that was not disclosed to shareholders before a patient suffered a fatal adverse event. The Company later announced an FDA clinical hold, triggering a nearly 37% stock price decline over two trading days. Individuals who purchased Rocket Pharmaceuticals securities during the Class Period from September 17, 2024 through May 26, 2025, may be eligible to join the class action. The deadline to file for lead plaintiff is August 11, 2025. To learn more about your rights, CLICK HERE. About Berger MontagueBerger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States. For more information or to discuss your rights, please contact:Andrew Abramowitz, Senior CounselBerger Montague(215) 875-3015[email protected] Caitlin AdorniBerger Montague(267) 764-4865[email protected] SOURCE Berger Montague WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News